Skip to main content
. 2023 Mar 23;45(1):2192285. doi: 10.1080/0886022X.2023.2192285

Table 5.

Subgroup analysis of the association between postoperative AKI and Dexmedetomidine.

    Model 1 Model 2 Model 3 Model 4
AKI
 
OR (95% CI) p value
  Non-Dex Dex
eGFR > 90 (mL/min),
n = 4908
1 0.50 (0.33, 0.75) <0.001 0.49 (0.32, 0.74) <0.001 0.49 (0.33, 0.75) <0.001 0.51 (0.37, 0.79) 0.003
Blood loss < 1000 mL,
n = 6384
1 0.62 (0.45, 0.86) 0.004 0.69 (0.50, 0.96) 0.029 0.70 (0.50, 0.98) 0.038 0.70 (0.50, 0.98) 0.039
NSAIDs = 0,
n = 5335
1 0.57 (0.41, 0.78) <0.001 0.65 (0.47, 0.90) <0.001 0.67 (0.49, 0.93) 0.018 0.67 (0.48, 0.95) 0.027

The association between postoperative AKI and Dexmedetomidine in different subgroups. Dex, Dexmedetomidine.

AKI stages (outcome of postoperative AKI was divided into four groups: stage 0, no AKI; stage 1, AKI grade 1; stage 2, AKI grade 2 and stage 3, AKI grade 3).

Model 1: non-adjusted.

Model 2: adjusted for age, sex, eGFR.

Model 3: model 2 plus hypertension, diabetes, diuretics.

Model 4: model 3 plus blood lossed, vasoactive drugs, Hb, Alb, amount of fluid infusion and out, operative time, ASA, lowest MAP and NSAIDs.